Pioneering Medicines: Drug Substance (Process Modeling) Co-Op
Flagship Pioneering, Inc.
Summary
We are seeking a motivated Drug Substance Co-Op with a chemical, biochemical, or biomedical engineering background and hands-on skill in in silico modeling of unit operations. This role will support Drug Substance process development in the CMC and Bioprocess Development group, using mechanistic and data-driven models to guide process design, scale-up, and tech transfer for biologics, small molecules, and peptides.
Job description
Position Description
We are seeking a motivated Drug Substance Co-Op with a chemical, biochemical, or biomedical engineering background and hands-on skill in in silico modeling of unit operations. This role will support Drug Substance process development in the CMC and Bioprocess Development group, using mechanistic and data-driven models to guide process design, scale-up, and tech transfer for biologics, small molecules, and peptides.
Key Responsibilities
In Silico Unit Operation Modeling
- Build, calibrate, and run models of drug substance unit operations (cell culture and fermentation, chromatography, ultrafiltration/diafiltration, viral inactivation and filtration, crystallization, peptide synthesis and purification) using mechanistic, hybrid, or statistical approaches.
- Use models to evaluate operating ranges, identify sensitive process parameters, and compare scale-up and scale-down options.
- Run sensitivity analyses and simulation-based studies to support process characterization and design-space thinking.
Data Analysis & Process Understanding
- Collect, clean, and analyze lab, pilot, and CDMO batch data to fit and verify models.
- Apply statistical tools and design of experiments (DoE) to plan and interpret studies.
- Summarize model results, assumptions, and limitations in clear technical reports and presentations.
Tech Transfer & CDMO Support
- Support tech transfer by translating model outputs into process descriptions, parameter ranges, and risk assessments for CDMO partners.
- Help review batch records and process data from external manufacturing sites and flag deviations from model predictions.
Documentation & Cross-Functional Collaboration
- Document model structure, inputs, and verification in line with good scientific and data integrity (ALCOA) practices.
- Contribute to CMC content such as process development summaries and risk assessments.
- Partner with Analytical Development, Drug Product, Quality, and Regulatory colleagues to connect model outputs with CQAs, control strategy, and program timelines.
Qualifications
Required
- Currently enrolled in a BS, MS, or PhD program in Chemical Engineering, Biochemical Engineering, Biomedical Engineering, or a closely related discipline.
- Coursework or project experience in transport phenomena, reaction engineering, thermodynamics, separations, or bioprocess engineering.
- Demonstrated skill in in silico modeling of unit operations for at least one modality (biologics, small molecules, or peptides), through coursework, research, or prior internships.
- Proficiency in at least one modeling or programming environment such as Python, MATLAB, or R, and/or process simulation tools (Aspen, gPROMS, SuperPro Designer, or COMSOL).
- Working knowledge of statistics and data analysis, including regression, parameter estimation, and sensitivity analysis.
- Strong written and verbal communication skills, with the ability to explain modeling assumptions and results to non-modelers.
- Ability to work independently and collaboratively in a fast-paced, matrixed environment.
Preferred Skills
- Experience with mechanistic modeling of chromatography, filtration, bioreactor, or crystallization processes, or with peptide or small-molecule reaction and purification modeling.
- Familiarity with hybrid or machine-learning approaches to process modeling, and with design of experiments tools such as JMP.
- Exposure to QbD concepts, including QTPP, CQAs, critical process parameters, and ICH Q8, Q9, and Q11.
- Familiarity with analytical methods used to characterize proteins, peptides, or small molecules.
- Prior experience in a laboratory, pilot plant, or industry setting.
Requirements
- Currently enrolled in a BS, MS, or PhD program in Chemical Engineering, Biochemical Engineering, Biomedical Engineering, or a closely related discipline
- Coursework or project experience in transport phenomena, reaction engineering, thermodynamics, separations, or bioprocess engineering
- Demonstrated skill in in silico modeling of unit operations for at least one modality (biologics, small molecules, or peptides)
- Proficiency in at least one modeling or programming environment such as Python, MATLAB, or R, and/or process simulation tools (Aspen, gPROMS, SuperPro Designer, or COMSOL)
- Working knowledge of statistics and data analysis, including regression, parameter estimation, and sensitivity analysis
- Strong written and verbal communication skills
- Ability to work independently and collaboratively in a fast-paced, matrixed environment
- Open exclusively to current Northeastern University Co-Op students
Benefits
- 401(k) Retirement Benefits
- Mentorship
- Professional Development Track
Company overview
Flagship Pioneering is a pioneering biotechnology venture capital firm that specializes in conceiving, creating, and developing first-in-category life sciences companies. Founded in 2000 and headquartered in Cambridge, Massachusetts, the firm applies a unique hypothesis-driven innovation process to originate and foster scientific ventures with transformative potential for human health and sustainability. Flagship has originated over 100 scientific ventures since its inception, creating more than $30 billion in aggregate value across its portfolio. The firm's ecosystem includes notable companies such as Moderna Therapeutics, Denali Therapeutics, Evelo Biosciences, and Seres Therapeutics, among others. Flagship operates through a systematic entrepreneurship model that combines scientific creativity, technological ingenuity, and executive leadership to build platform companies capable of generating multiple breakthrough products. With over $3 billion in aggregate capital commitments, the firm invests primarily in therapeutics, health technologies, and sustainability sectors, working in partnership with academic institutions, pharmaceutical companies, and investment communities to advance groundbreaking science and innovation globally.